[HTML][HTML] Vaccination and immunotherapies in neuroimmunological diseases
A Winkelmann, M Loebermann, M Barnett… - Nature Reviews …, 2022 - nature.com
Neuroimmunological diseases and their treatment compromise the immune system, thereby
increasing the risk of infections and serious illness. Consequently, vaccinations to protect …
increasing the risk of infections and serious illness. Consequently, vaccinations to protect …
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
S Otero-Romero, C Lebrun-Frénay… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Background: With the new highly active drugs available for people with multiple sclerosis
(pwMS), vaccination becomes an essential part of the risk management strategy Objective …
(pwMS), vaccination becomes an essential part of the risk management strategy Objective …
[HTML][HTML] Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
JJ Sabatino Jr, K Mittl, WM Rowles, K McPolin… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-
CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially …
CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially …
Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab
N Madelon, N Heikkilä, IS Royo, P Fontannaz… - JAMA …, 2022 - jamanetwork.com
Importance The SARS-CoV-2 variant B. 1.1. 529 (Omicron) escapes neutralizing antibodies
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …
Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease
Background and Objectives Rituximab is used widely for relapse prevention in neuromyelitis
optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG …
optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG …
B cell depletion and SARS‐CoV‐2 vaccine responses in neuroimmunologic patients
B Kornek, F Leutmezer, PS Rommer… - Annals of …, 2022 - Wiley Online Library
Objective The study was undertaken to assess the impact of B cell depletion on humoral and
cellular immune responses to severe acute respiratory syndrome‐coronavirus 2 (SARS …
cellular immune responses to severe acute respiratory syndrome‐coronavirus 2 (SARS …
[HTML][HTML] Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
NJM Verstegen, RR Hagen, J van den Dijssel… - Elife, 2022 - elifesciences.org
Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …
[HTML][HTML] Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis: an Israeli multi-center experience following 3 …
R Milo, E Staun-Ram, D Karussis, A Karni… - Frontiers in …, 2022 - frontiersin.org
Background Immunomodulatory/immunosuppressive activity of multiple sclerosis (MS)
disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 …
disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 …
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
A Garjani, S Patel, D Bharkhada, W Rashid… - Multiple sclerosis and …, 2022 - Elsevier
Background Contradicting assumptions have been made about the effectiveness of SARS-
CoV-2 vaccines in patients with multiple sclerosis (MS) receiving immunomodulatory …
CoV-2 vaccines in patients with multiple sclerosis (MS) receiving immunomodulatory …
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
M Etemadifar, H Nouri, M Pitzalis, ML Idda… - Journal of Neurology …, 2022 - jnnp.bmj.com
Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …